_pptx-Photoroom.png)
Mission
To harness the untapped immune intelligence of red blood cells to detect, monitor, and treat disease with precision and accessibility.
Vision
To transform how the world understands and uses red blood cells - from silent carriers to central players in modern medicine.
2009:
Discovery of the immune
role of red blood cells
2023:
Early-access clinical deployment through CLIA pathways
2017–2020:
Preclinical proof-of-concept studies validating diagnostic accuracy and therapeutic potential
2024–2025:
FDA submissions for
diagnostics in lung, cervical,
and pancreatic cancers
2022:
Expansion into RNA payloads and early sepsis detection models
2026+:
Pipeline growth into autoimmune, prenatal, and neurological diseases; partnership and global licensing
Timeline &
Pipeline
Founded on groundbreaking research at the University of Pennsylvania, Senticell is building a new class of diagnostics and therapeutics based on the immune intelligence of RBCs.
What is Senticell
Our Science
Why RBCs? Red blood cells are the body’s most abundant immune messengers. They access tissue microenvironments, are immune-silent, and reveal early molecular changes.
Diagnostic Platform
A next-gen, ultra-sensitive, same-day PCR solution that uses RBCs to amplify molecular signals in disease.
Therapeutic Platform
Modulates immune activity and delivers RNA/drug payloads via modified RBCs for targeted action.
Disease Focus Section
Disease
Cancer
Lung, Cervical, Pancreatic, H&N:
Infectious Disease
Sepsis, Tuberculosis, COVID-19
Autoimmune
SLE (Lupus), Sickle Cell Anemia
Prenatal
Early screening with non-invasive sampling
Neurology
RNA fusions for neurodegenerative diseases
Get to Know Us, Meet
Our Team
Nilam Mangalmurti, MD
Inventor, Founder, Chief Scientific Officer
-
Founded the field of RBC immunobiology
-
Critical care specialist, pulmonary specialist
-
ASCI Member
Steven Albelda, MD
Scientific Advisor
-
Scientific Advisor to Verismo Therapeutics and Bio4
-
Co-founder, Capstan
-
Tumor immunologist, lung cancer, immunotherapy, CAR T cells (co-founder of Capstan)
-
Wagner Award from the International Mesothelioma Interest Group
Chris Hunter, PhD
Scientific Advisor
-
Cytokine biologist, inflammation expert, immunologist
-
Founder at Surface Oncology (acquired by Coherus)
-
Scientific Advisor for Anaptsys Bio, CytomX, Coherus, ArsenalBio and Synthekine
Neha Shah, MBA
Co-founder, Chief Executive Officer
-
25 year exited entrepreneur from GEP supporting biotech and large pharma customers – JNJ, BMS, Roche,& many more
-
Board Chair, McNulty Leadership Program, The Wharton School
-
Henry Crown Fellow, Aspen Institute
--
International Biotech expert and advisor
Describe the team member here. Write a brief description of their role and responsibilities, or a short bio with a background summary.
--
COO TBC
Describe the team member here. Write a brief description of their role and responsibilities, or a short bio with a background summary.
News &
Publications
Describe the service and how customers or clients can benefit from it. This is the place to add a short description with relevant details, like pricing, duration and how to book.
Language Translation
Chatbots
Describe the service and how customers or clients can benefit from it. This is the place to add a short description with relevant details, like pricing, duration and how to book.
Describe the service and how customers or clients can benefit from it. This is the place to add a short description with relevant details, like pricing, duration and how to book.